Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes
Schiller, Gary J. , Slack, James L., Hainsworth, John D. , Mason, James R. , Rizzieri, David A. , Douer, Dan , List, Alan F. , Saleh, Mansoor N.

Mayo Clinic

Journal of Clinical Oncology | May 2, 2006 | Volume: 24 | Issue: 16 | Pages: 2456-2464

10.1200/jco.2005.03.7903 | PMID 16651647 Get It

Purpose To evaluate the efficacy and safety of arsenic trioxide monotherapy in patients with myelodysplastic syndromes (MDS). Patients and Methods Patients received arsenic trioxide (0.25 mg/kg/d) on 5 consecutive days per week for 2 weeks, followed by 2 weeks’ rest (one cycle). Two patient cohorts were established according to International Prognostic Scoring System risk category: lower-risk (low or intermediate-1) or higher-risk MDS (intermediate-2 or high). For lower-risk MDS, hematologic improvement (HI) was the primary response end point. For higher-risk MDS, additional end points included complete or partial remission. Based on the expected time to response, patients receiving two or more cycles were prospectively evaluated. Results Hematologic adverse events included neutropenia, thrombocytopenia, and febrile neutropenia. Two patients died during the study due to treatment-related toxicities. Most common grade 3/4 nonhematologic events were pneumonia, fatigue, hemorrhage, pain, and dyspnea. Among patients who received one or more doses (n = 70) or completed two or more cycles (n = 51), the HI rates were 34% and 39% in lower-risk patients, and 6% and 9% in higher-risk patients, respectively; the overall major HI rates were 20% and 22%. One higher-risk patient achieved a complete remission (3%). Major HIs were observed in all hematologic lineages; erythroid responses were the most common. Transfusion independence or reduction by ≥ 50% occurred in 33% of patients dependent on RBC transfusions. The overall median duration of HI was 6.8 months (range, 2 to 40 months). Conclusion Arsenic trioxide monotherapy has moderate activity against MDS, with a manageable adverse effect profile. The further study of arsenic trioxide in MDS, particularly in combination with other agents, is warranted.
Chronic Exposure to Lead Chromate Causes Centrosome Abnormalities and Aneuploidy in Human Lung Cells
Holmes, Amie L., Wise, Sandra S., Sandwick, Sarah J., Lingle, Wilma L., Negron, Vivian , Thompson, W. Douglas, Wise, John Pierce , Wise, Sandra S.

Mayo Clinic

Cancer Research | April 17, 2006 | Volume: 66 | Issue: 8 | Pages: 4041-4048

10.1158/0008-5472.can-05-3312 | PMID 16618723 Get It

Abstract Hexavalent chromium [Cr(VI)] compounds are established human lung carcinogens. The carcinogenicity of Cr(VI) is related to its solubility, with the most potent carcinogens being the insoluble particulate Cr(VI) compounds. However, it remains unknown why particulate Cr(VI) is more carcinogenic than soluble Cr(VI). One possible explanation is that particulates may provide more chronic exposures to chromate over time. We found that aneuploid cells increased in a concentration- and time-dependent manner after chronic exposure to lead chromate. Specifically, a 24-hour lead chromate exposure induced no aneugenic effect, whereas a 120-hour exposure to 0.5 and 1 μg/cm2 lead chromate induced 55% and 60% aneuploid metaphases, respectively. We also found that many of these aneuploid cells were able to continue to grow and form colonies. Centrosome defects are known to induce aneuploidy; therefore, we investigated the effects of chronic lead chromate exposure on centrosomes. We found that centrosome amplification in interphase and mitotic cells increased in a concentration- and time-dependent manner with 0.5 and 1 μg/cm2 lead chromate for 120 hours, inducing aberrant centrosomes in 18% and 21% of interphase cells and 32% and 69% of mitotic cells, respectively; however, lead oxide did not induce centrosome amplification in interphase or mitotic cells. There was also an increase in aberrant mitosis after chronic exposure to lead chromate with the emergence of disorganized anaphase and mitotic catastrophe. These data suggest that one possible mechanism for lead chromate–induced carcinogenesis is through centrosome dysfunction, leading to the induction of aneuploidy. (Cancer Res 2006; 66(8): 4041-8)
Acute Suppurative Thyroiditis Caused by Pasteurella multocida and Associated with Thyrotoxicosis
McLaughlin, Sarah A. , Meek, Shon , Smith, Stephen L.

Mayo Clinic

Thyroid | March 29, 2006 | Volume: 16 | Issue: 3 | Pages: 307-310

10.1089/thy.2006.16.307 | PMID 16571095 Get It

Validation of the UPPS impulsive behaviour scale: a four‐factor model of impulsivity
Whiteside, Stephen P., Lynam, Donald R. , Miller, Joshua D. , Reynolds, Sarah K.

Mayo Clinic

European Journal of Personality | December 12, 2005 | Volume: 19 | Issue: 7 | Pages: 559-574

10.1002/per.556 Get It

The current study attempts to clarify the multi‐faceted nature of impulsivity through the use of the four‐factor UPPS Impulsive Behaviour scale. In order to build the nomological network surrounding this scale, the UPPS was administered to individuals with borderline personality disorder (BPD), pathological gamblers (PG), alcohol abusers (divided into two groups based on the presence of antisocial features), and a control group. Several of the UPPS scales (e.g. Urgency, lack of Premeditation, and Sensation Seeking) differentiated the BPD, PG, and alcohol abusers with antisocial features from a group of non‐antisocial alcohol abusers and a control group. Overall, the UPPS scales accounted for between 7% (pathological gambling) and 64% (borderline personality disorder features) of the overall variance in the psychopathology measures. Individual UPPS scales also made unique contributions to several of these disorders, which may provide insight into which of these personality traits may predispose individuals to behave in maladaptive or problematic ways. The results provide support for the differentiation of impulsivity‐related constructs into the current four‐factor model. Copyright © 2005 John Wiley & Sons, Ltd.
Human TopBP1 Ensures Genome Integrity during Normal S Phase
Kim, Ja‐Eun , McAvoy, Sarah , Smith, David I., Smith, David I., Chen, Junjie

Mayo Clinic

Molecular and Cellular Biology | November 28, 2005 | Volume: 25 | Issue: 24 | Pages: 10907-10915

10.1128/mcb.25.24.10907-10915.2005 | PMID 16314514 Get It

A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk
Narla, Goutham , DiFeo, Analisa , Reeves, Helen L. , Schaid, Daniel J. , Hirshfeld, Jennifer, Hod, Eldad A. , Katz, Amanda, Isaacs, William B., Hebbring, Scott J. , Komiya, Akira , McDonnell, Shannon K. , Wiley, Kathleen E. , Jacobsen, Steven J. , Isaacs, Sarah D., Walsh, Patrick C., Chang, Bao-Li, Friedrichsen, Danielle M., Stanford, Janet L. , Ostrander, Elaine A. , Chinnaiyan, Arul M., Rubin, Mark A. , Xu, Jianfeng , Thibodeau, Stephen N. , Martignetti, John A., Karyadi, Danielle M. , Zheng, Shusen , Chang, Bao‐Li, Friedman, Scott L. , DiFeo, Analisa , Rubin, Mark A , McDonnell, Shannon K

Mayo Clinic

Cancer Research | September 15, 2005 | Volume: 65 | Issue: 4 | Pages: 1213-1222

10.1158/0008-5472.can-04-4249 | PMID 15735005 Get It

Abstract Prostate cancer is a leading and increasingly prevalent cause of cancer death in men. Whereas family history of disease is one of the strongest prostate cancer risk factors and suggests a hereditary component, the predisposing genetic factors remain unknown. We first showed that KLF6 is a tumor suppressor somatically inactivated in prostate cancer and since then, its functional loss has been further established in prostate cancer cell lines and other human cancers. Wild-type KLF6, but not patient-derived mutants, suppresses cell growth through p53-independent transactivation of p21. Here we show that a germline KLF6 single nucleotide polymorphism, confirmed in a tri-institutional study of 3,411 men, is significantly associated with an increased relative risk of prostate cancer in men, regardless of family history of disease. This prostate cancer–associated allele generates a novel functional SRp40 DNA binding site and increases transcription of three alternatively spliced KLF6 isoforms. The KLF6 variant proteins KLF6-SV1 and KLF6-SV2 are mislocalized to the cytoplasm, antagonize wtKLF6 function, leading to decreased p21 expression and increased cell growth, and are up-regulated in tumor versus normal prostatic tissue. Thus, these results are the first to identify a novel mechanism of self-encoded tumor suppressor gene inactivation and link a relatively common single nucleotide polymorphism to both regulation of alternative splicing and an increased risk in a major human cancer.
Iqmik – A form of smokeless tobacco used by pregnant Alaska natives: Nicotine exposure in their neonates
Hurt, R. Douglas , Renner, Caroline C., Ebbert, Jon O. , Offord, Kenneth P., Schroeder, Darrell R. , Enoch, Carrie, Gill, Leigh, Angstman, Sarah, Moyer, Thomas P. , Patten, Christi A. , Schroeder, Darrell

Mayo Clinic

The Journal of Maternal-Fetal & Neonatal Medicine | September 7, 2005 | Volume: 17 | Issue: 4 | Pages: 281-289

10.1080/14767050500123731 | PMID 16147838 Get It

Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
Dewald, Gordon W., Therneau, Terry M. , Lee, You Kyoung , Fink, Stephanie, Smoley, Stephanie A., Paternoster, Sarah F., Adeyinka, Adewale, Ketterling, Rhett P. , Dyke, Daniel L. Van , Fonseca, Rafaël , Kyle, Robert A. , Larson, Dirk R. , Ketterling, Rhett P , Fonseca, Rafael

Mayo Clinic

Blood | July 20, 2005 | Volume: 106 | Issue: 10 | Pages: 3553-3558

10.1182/blood-2005-05-1981 | PMID 16030187 Get It

AbstractThe clinical efficacy of evaluating genetic anomalies in metaphase cells versus interphase nuclei for multiple myeloma (MM) is poorly understood. Therefore, survival for 154 patients with newly diagnosed untreated MM was compared with results from analysis of metaphase and interphase cells. Metaphases were studied by conventional cytogenetics and fluorescent-labeled DNA probes (fluorescence in situ hybridization [FISH]), whereas inter-phase nuclei were evaluated only by FISH. All FISH studies were done using DNA probes to detect t(4;14)(p16;q32), t(11;14)(q13;q32), t(14;16)(q32;q23), del(17) (p13.1), and chromosome 13 anomalies. Metaphases were abnormal by cytogenetics and/or metaphase FISH in 61 (40%) patients. Abnormal interphase nuclei were observed in 133 (86%) patients, including each patient with abnormal metaphases. FISH was a necessary adjunct to cytogenetics to detect t(4;14) and t(14;16) in metaphase cells. Patient survival was especially poor for patients with greater than 50% abnormal interphase nuclei, although this result was more likely due to level of plasma cells than specific chromosome anomalies. For metaphase data, patients with t(4;14), t(14;16), del(17) (p13.1), and/or chromosome 13 anomalies (primarily monosomy 13) had poor survival. A different outcome was observed for interphase data as patients with t(4;14) or t(14;16) had poor survival, whereas patients with chromosome 13 anomalies had intermediate survival: interphase FISH did not substitute for metaphase analysis.
Vision screening for correctable visual acuity deficits in school-age children and adolescents
Powell, Christine, Wedner, Susanne H., Hatt, Sarah R.

Mayo Clinic

Cochrane Database of Systematic Reviews | January 17, 2005 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd005023.pub2 | PMID 15654703 Get It

Outcome of Surgical Treatment for Primary Malignant Melanoma of the Female Urethra
DiMarco, David S., DiMarco, Connie S., Zincke, Horst, Webb, Maurice J., Keeney, Gary L., Bass, Sarah E., Lightner, Deborah J.

Mayo Clinic

Journal of Urology | August 25, 2004 | Volume: 171 | Issue: 2 | Pages: 765-767

10.1097/01.ju.0000104671.20863.47 | PMID 14713806 Get It